Vaxfab Enterprises Ltd

Vaxfab Enterprises Ltd announced that its Board of Directors, in a meeting held on May 30, 2026, approved the audited financial results for the quarter and year ended March 31, 2026. The company's statutory auditor, M/S Chandabhoy & Jassoobhoy, issued an unmodified audit report on both standalone and consolidated financial results. However, the auditor issued a disclaimer of opinion on the standalone financial results due to a lack of sufficient audit evidence, citing issues with prior period records, inadequate maintenance of books of account, and unsecured loans without formal agreements.

Vaxfab Enterprises Ltd has announced the closure of its trading window for all designated persons, including directors and promoters, and their relatives. This closure is in accordance with the company's internal code of conduct for preventing insider trading and SEBI regulations. The trading window will remain shut from July 01, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ended June 30, 2026. This measure is intended to prevent potential misuse of unpublished price-sensitive information.

Vaxfab Enterprises Ltd's Board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The auditor, M/S Chandabhoy & Jassoobhoy, issued an audit report with a disclaimer of opinion due to inadequacies in prior period records and other issues. The auditor was unable to obtain sufficient appropriate audit evidence regarding the completeness, accuracy, and recoverability of related balances and transactions.

Vaxfab Enterprises Ltd has announced that a meeting of its Board of Directors is scheduled for May 30, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The trading window for dealing in the company's securities has been closed since April 1, 2026, and will remain closed until 48 hours after the financial results are submitted.

Vaxfab Enterprises Ltd has issued a clarification regarding the allotment of 14,81,068 Equity Shares at a price of ₹21.02 per share, pursuant to the conversion of warrants on a preferential basis. The company identified a typographical error in the initially reported total number of equity shares allotted. Post correction, the paid-up equity share capital of the company stands at ₹24,99,96,450, comprising 2,49,99,645 Equity Shares of face value ₹10 each. All other terms and conditions of the allotment remain unchanged.

Vaxfab Enterprises Ltd has allotted 19,50,348 equity shares at ₹21.02 each upon conversion of warrants on a preferential basis. This increases the company's paid-up equity share capital to ₹25,46,89,250, comprising 2,54,68,925 equity shares of ₹10 each. The allotment was approved at the Board Meeting held on May 11, 2026.

Vaxfab Enterprises Ltd has allotted 13,18,550 equity shares at ₹21.02 each upon conversion of warrants on a preferential basis. Following the allotment, the paid-up equity share capital increased to ₹23,51,85,770, comprising 2,35,18,577 equity shares. The allotment was approved at a board meeting held on April 24, 2026, which commenced at 10:10 A.M. and concluded at 10:40 A.M.

Vaxfab Enterprises Ltd's Board of Directors approved the allotment of 1,318,550 fully paid-up equity shares, each with a face value of ₹10, at a price of ₹21.02 per share. These shares were issued upon the conversion of warrants on a preferential basis to 11 investors. Following this allotment, the company's paid-up equity share capital has increased to ₹23,51,85,770, comprising 23,518,577 equity shares. The newly allotted shares will rank pari-passu with the existing equity shares of the company.

Vaxfab Enterprises Ltd. announced the allotment of 1,318,550 fully paid-up equity shares, each with a face value of ₹10, at a price of ₹21.02. These shares were issued upon the conversion of warrants on a preferential basis to 11 investors. This corporate action has increased the company's paid-up equity share capital to ₹23,51,85,770, comprising 23,518,577 equity shares. The newly allotted shares will rank pari-passu with existing equity shares.

Vaxfab Enterprises Ltd's Board approved the allotment of 1,328,861 fully paid-up equity shares of 10 face value at 21.02 each. These shares were issued upon the conversion of warrants on a preferential basis to investors. This allotment increases the company's paid-up equity share capital to 22,20,00,270, comprising 22,200,027 equity shares. The newly allotted shares will rank pari-passu with existing equity shares.